The impact of transfusion of leucodepleted platelet concentrates on cytomegalovirus disease after allogeneic stem cell transplantation.
The impact of transfusion of leucodepleted platelet concentrates (PCs) on cytomegalovirus (CMV) disease was assessed in 215 allogeneic (145 unrelated and 70 related donor) transplants over 3 years. In 43%, both donor and patient were CMV seronegative (CMV-/-). All received CMV-seronegative red cells and random leucodepleted PCs. No CMV disease occurred in any CMV-/- (low risk) transplant. CMV infection occurred in 31 seropositive patients (26%); 13 died and five deaths were attributable to CMV disease. When compared with historical controls, who received CMV-seronegative PCs, we found no difference in transfusion-acquired CMV in the current cohort.
BMT Unit, Bristol Royal Hospital for Children, Bristol, UK.
Milind D
MD
Ronghe
Annabel B M
AB
Foot
Jaqueline M
JM
Cornish
Colin G
CG
Steward
David
D
Carrington
Nicholas
N
Goulden
David I
DI
Marks
Anthony
A
Oakhill
D000212:Acyclovir / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000628:therapy*; D005260:Female; D017245:Foscarnet / Q000627:therapeutic use; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008212:Lymphocyte Depletion; D008297:Male; D008875:Middle Aged; D017713:Platelet Transfusion; D011183:Postoperative Complications / Q000628:therapy*; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous
D000998:Antiviral Agents; D017245:Foscarnet; D015774:Ganciclovir; D000212:Acyclovir